Navigating AI Act Implementation Challenges in MedTech

By HEOR Staff Writer

August 5, 2025

MedTech Europe recently marked the first anniversary of the EU Artificial Intelligence Act (AI Act). It highlights challenges in implementing the AI Act, such as regulatory overlap with the Medical Devices Regulation (MDR)/IVDR frameworks. This overlap could delay patient access to innovative medical technologies. The organization calls for clearer exemptions for clinical investigations and performance studies under the AI Act. Aligned implementation is needed to foster AI-driven advancements in diagnostics and treatment.

Key Insights

The AI Act’s post-implementation phase risks creating conflicting obligations for manufacturers of high-risk AI systems in medical devices. Overlapping requirements between MDR/IVDR and the AI Act complicate compliance. MedTech Europe stresses the need for legal clarity to prevent regulatory bottlenecks, especially for clinical studies. These studies are critical for developing safe and effective technologies. Other challenges include data quality, interoperability, and resource disparities across EU member states. Targeted support is also needed for under-resourced regions.

The AI Act entered into force on August 1, 2024, and high-risk AI systems in medical devices must comply by August 2027. Existing regulations like MDR/IVDR already govern medical AI tools but lack alignment with the AI Act’s requirements. Challenges persist in data infrastructure and clinical workflow integration. Germany, for example, struggles with fragmented health data and insufficient public health AI applications.

Implications

Overlapping regulations could escalate administrative burdens for manufacturers. This might delay the deployment of AI-driven diagnostic tools and worsen health disparities. Prolonged compliance processes could increase costs and slow innovation. Effective implementation, however, could enhance safety and interoperability. Harmonized oversight by the European AI Office is crucial, and aligning AI Act requirements with MDR/IVDR would help maintain Europe’s position as a hub for medical AI innovation.

For further insights, explore MedTech Europe’s article here.

Reference url

Recent Posts

FDA Approval Lumvoa Therapeutics
FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease

By João L. Carapinha

June 29, 2026

The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.
HIV Treatment Access
Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

By João L. Carapinha

June 29, 2026

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.
EMA CHMP Meeting Highlights
Regulatory Insights from EMA CHMP Meeting Highlights

By HEOR Staff Writer

June 26, 2026

The EMA CHMP Meeting Highlights from 22-25 June 2026 show the committee advancing six new medicines while maintaining rigorous evidentiary standards for complex and rare conditions. Positive opinions covered an inactivated influenza vaccine for adults 50 and older, a levodopa-carbidopa intestinal...